Source link : https://www.newshealth.biz/health-news/fda-panel-votes-for-limits-on-some-gi-cancer-immunotherapy/
Late last week, a US Food and Drug Administration (FDA) panel met to discuss whether to limit the use of nivolumab (Opdivo) and pembrolizumab (Keytruda) in patients with unresectable or metastatic esophageal squamous cell carcinoma and human epidermal growth factor receptor 2 (HER2)–negative, microsatellite stable gastric/gastroesophageal adenocarcinoma. During the meeting, the FDA’s Oncologic Drugs Advisory […]
Author : News Health
Publish date : 2024-09-30 11:32:09
Copyright for syndicated content belongs to the linked Source.
Categories